The European Patent Office grants patent for intralymphatic administration of the diabetes vaccine Diamyd®

The granted patent is valid until 2035 and provides central protection for the diabetes vaccine Diamyd[®]. In paticlular, the patent protects the intralymphatic administration method that is now being evaluated in the Phase IIb trial DIAGNODE-2 and which previously showed positive results in the Phase I/II trial DIAGNODE-1.“These news are very gratifying”, says Ulf Hannelius, CEO of Diamyd Medical. “The patent gives us extended protection for the diabetes vaccine Diamyd[®] in Europe, one of the most important pharmaceutical markets in the world”. Diamyd Medical already holds, as part of